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Summary The cell cycle regulatory proteins p16 and p21 cause cell cycle arrest at the G, checkpoint by
inhibiting activity of cyclin D-CDK4 complexes. The TP53 gene, regulating the p21 protein, is mutated at
high frequency in ovarian cancer. The CDKN2 gene, encoding the p16 protein, has been mapped to
chromosome 9p2l and encompasses three exons. To establish the frequency of CDKN2 gene abnormalities in
ovarian tumour specimens, we have studied this gene in five ovarian cancer cell lines and in 32 primary and five
metastatic ovarian adenocarcinomas. Using polymerase chain reaction-single strand conformation
polymorphism (PCR- SSCP) and sequencing techniques both exon 1 and 2 of the CDKN2 gene, encompassing
97% of the coding sequence, were analysed. In addition, the TP53 gene was studied for the presence of
mutations. The cell line HOC-7 showed a 16 bp deletion in exon 2 of the CDKN2 gene, resulting in a stop
codon, whereas in cell line SK-OV-3 this gene was found to be homozygously deleted. Nine primary tumour
specimens showed a migration shift on SSCP. Sequencing revealed a common polymorphism (Alal48Thr) in
seven of these ovarian tumour specimens. The two other tumour samples were found to contain silent
mutations, one at codon 23 (GGT-.GGA) and the other at codon 67 (GGC-+GGT). Mutations in the TP53
gene were observed in 46% of the ovarian tumour specimens. We conclude that CDKN2 gene alterations are
rare events in human ovarian cancer. The low prevalence of these alterations do not allow for analysis of an
association of this gene with prognosis.
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Cyclins, cyclin-dependent kinases (CDKs) and cyclin-
dependent kinase inhibitors (CKIs) play a key role in cell
cycle control. To achieve an orderly progression through the
cell cycle, different cyclin -CDK complexes need to be
activated and deactivated at appropriate times. Cyclin D-
CDK4 is one of the complexes that promotes cell passage
through the G1 phase of the cell cycle. It increases the
phosphorylation state of the retinoblastoma protein which
then releases transcription factors (e.g. E2F) essential for
progression into the S-phase (reviewed by Sherr, 1993;
Hartwell and Kastan, 1994; Hunter and pines, 1994).
Changes in the amount or composition of CDKs or their
inhibitors may lead to loss of cell cycle control and thus to
uncontrolled cell growth.
One of the inhibitors of cyclin D -CDK4 as well as of
other cyclin -CDK complexes throughout the whole cell cycle
is the p21 protein, encoded by the WAF1 (CIPI/SDI1) gene
(El-Deiry et al., 1993; Harper et al., 1993; Xiong et al., 1993).
Upon genotoxic damage, expression of p21 is induced
through the transcriptional activation by TP53Wt (El-Deiry
et al., 1994). The TP53 gene is located on chromosome
17pl3.1 and mutation of this gene is the most common
genetic abnormality yet found in human cancers. The
prevalence of TP53 mutations varies among tumour types
with roughly 44% of ovarian tumours being mutated
(reviewed by Greenblatt et al., 1994).
Another negative regulator of cyclin D-CDK4/6 activity
is the p16 protein, encoded by the CDKN2 (MTSIpl6in'k4/
CDK4I) gene (Serrano et al., 1993; Nobori et al., 1994). The
CDKN2 gene, which has been mapped to chromosome 9p2l,
was found to be deleted or mutated in a wide variety of
tumour cell lines, including nearly 30% of ovarian cancer cell
lines (Kamb et al., 1994). Interestingly, loss of heterozygosity
(LOH) at 9p has been reported in 31% (49 out of 157) of
human epithelial ovarian tumours (reviewed by Shelling et
al., 1995).
To determine whether alterations of the CDKN2 gene are
involved in ovarian carcinogenesis, we have studied this gene
in 32 primary and five metastatic human epithelial ovarian
tumour specimens and in an additional five ovarian cancer
cell lines. To this end, exons 1 and 2, constituting 97% of the
coding sequence, were examined using PCR-SSCP and
sequencing techniques. Our results suggest that alterations
of the CDKN2 gene play no major role in the initiation or
progression of ovarian cancer.
Materials and methods
Cell lines
The human ovarian cancer cell lines used in this study were
SK-OV-3 (HTB-77), SK-OV-6, 2780, 2774, HOC-7 (a gift
from Dr Gunther Daxenbichler, Innsbruck, Austria). The
SK-OV-3 and HOC-7 cell lines originated from ascites,
whereas the other cell lines were derived from (ade-
no)carcinomas (ATCC).
Tumour samples
Thirty-two primary and five metastatic ovarian adenocarci-
nomas were included in this study. One patient had bilateral
adenocarcinoma of the same histological type. A sample of
both locations was investigated. The mean age as well as the
median age of the patients with ovarian tumours was 56
years (range, 26-85 years). Following the WHO (1979)
classification the primary and metastatic carcinomas were
subtyped into serous (n = 14 primary, n = 5 metastatic),
mucinous (n =4), endometroid (n =7), clear cell (n =2),
mixed (n =3), poorly differentiated (n = 1) and unknown
(n = 1). To estimate the percentage of tumour cells, frozen
sections were made from a representative part of each
tumour and stained with haematoxylin and eosin. The
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percentages of tumour cells in the primary tumour speci-
mens were: below 25% (n =8), between 25% and 50%
(n=3), between 50% and 75% (n=8) and above 75%
(n = 12). With respect to the metastatic tumour specimens,
the percentages of tumour cells were: between 50% and 75%
(n=3) and above 75% (n =2). In general, 68% of these
tumours contained over 50% of tumour cells.
DNA extraction, polymerase chain reaction (PCR), single
strand conformation polymorphism (SSCP) analysis and
sequence analysis
Tumour specimens were stored in liquid nitrogen. Genomic
DNA was extracted from frozen tumour tissues or cell lines
according to standard procedures (Sambrook et al., 1989).
Exons 1 (150 bp) and 2 (307 bp) ofthe CDKN2 gene (Okamoto
et al., 1994) as well as exons 5, 6, 7 and 8 ofthe TP53 gene were
studied by PCR- SSCP analysis (Orita et al., 1989). Locations
and sequences of PCR-primers for exon 1 (Okamoto et al.,
1994) and forexon 2 (Berns etal., 1995) ofthe CDKN2gene are
shown in Figure 1 and Table I respectively.
Briefly, exon 1 was amplified by PCR using intronic
primer pairs (Okamoto et al., 1994) as shown in Table I.
Exon 2 was amplified using primer pair M2-U/M2-D,
generating a 522 bp fragment. To enhance specificity and
to generate smaller fragments, two nested PCRs were
carried out using primer pairs A1/A2 and B1/M2-D.
About 200 ng genomic DNA was used for PCR.
Amplification was performed in the presence of 10%
dimethyl sulphoxide (DMSO) and [oc32P]dATP using a
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Figure 1 Top: Primer locations for amplification of exon 1 and exon 2 of the CDKN2 gene as described in the Materials and
methods section. Bottom: Examples of PCR-SSCP analyses of CDKN2 fragments. (a) A migration shift in exon 1. (b and c)
Migration shifts in exon 2. The corresponding sequence analyses are shown in Figure 2. The asterisks indicate the altered migration
patterns. D, denatured; ND, not denatured.
Table I Primer sequences and cycling parameters for amplification of exon 1 and exon 2 of the CDKN2 gene
Exon Primer sequences Cycling parameters
1 Ml-U: 5'-CGGAGAGGGGGAGAGCAG-3' 50 s 92°C, 30 s 60°C, 2 min 72°C,
MI-D: 5'-TCCCCTTTTTCCGGAGAATCG-3' 30 cycles
2 M2-U: 5'-GAGAACTCAAGAAGGAAATTGG-3' 50 s 92°C, 50 s 57°C, 2 min 72°C,
M2-D: 5'-TCTGAGCTTTGGAAGCTCTCA-3' 30 cycles
Nested primers
Al: 5'-AGCTTCCTTTCCGTCATGC-3' 50 s 92°C, 50 s 57°C, 2 min 72°C,
A2: 5'-ACCACCAGCGTGTCCAGGAAG-3' 20 cycles
Bl: 5'-ACTCTCACCCGACCCGTG-3' 50 s 92°C, 50 s 57°C, 2 min 72°C,
M2-D: 5'-TCTGAGCTTTGGAAGCTCTCA-3' 20 cycles
A2
Bi
M2-D 4--
M2-D
4-DNA thermal cycler-480 (Perkin Elmer/Cetus, Norwalk,
CT, USA). To improve specific annealing, a touchdown
PCR procedure was used. Cycling parameters are listed in
Table I. Genomic input DNA and PCR product ratios
were compared on ethidium bromide-stained agarose gels
(1.3%) following the first 30 cycles of PCR. The breast
cancer cell lines, MCF7 and MDA-MB-231, which have a
homozygous deletion of the CDKN2 gene (Berns et al.,
1995), were taken as a control.
The exons 5, 6, 7, and 8 of the TP53 gene were amplified
using commercially available primers (Clontech, Palo Alto,
CA, USA). To obtain a false negative rate below 10%,
products of less then 200 bp were generated (Hayashi and
Yandell 1993). To this end, the TP53 PCR products were
digested with HinfI (exon 5), HaeIII (exon 6) and BsrI (exon
8). Exon 1 of the CDKN2 gene was digested with BsrI and
exon 2 (fragment BI/M2-D) was digested with KpnI. For
SSCP analysis 32P-labelled PCR products were heat
denatured and applied to a non-denaturing 8% polyacryla-
mide gel containing 10% (v/v) glycerol and electrophoresis
was performed at 30 W for 6 h at room temperature. PCR
products showing an altered electrophoretic mobility were
analysed again and then subcloned into a TA cloning vector
(PCRII; Invitrogen, San Diego, CA, USA). At least ten
individual clones were pooled and sequenced by double-
stranded sequencing (T7 sequencing kit; Pharmacia, Uppsala,
Sweden) using a 6% denaturing polyacrylamide gel contain-
ing 8 M urea.
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Results
We have studied alterations in exons 1 and 2 of the CDKN2
gene in 32 primary and five metastatic ovarian adenocarci-
nomas and in five ovarian cancer cell lines using PCR-SSCP
and sequencing techniques.
Two cell lines, SK-OV-3 and HOC-7, showed alterations
in the CDKN2 gene. No PCR products for exon 1 and 2
could be generated using the cell line SK-OV-3, indicating
that the CDKN2 gene is homozygously deleted in this cell
line. The integrity of the DNA was confirmed by a successful
amplification of TP53 (exons 5-8). The cell line HOC-7 was
found to have a 16 bp deletion in exon 2 ofthe CDKN2 gene.
This deletion removes nucleotides at positions 163- 178,
thereby placing the sequence in a different reading frame and
introducing a stop codon 256 bp downstream from the
deletion. In addition, this cell line also has a mutation
(T-.A) 36 bp downstream of this deletion.
Among the 32 primary tumours examined a total of nine
(28%) altered migration patterns were detected (Figure 1 and
Table II). Two mobility shifts correlated with silent
mutations in exon 1 (codon 23:GGT-÷GGA) and exon 2
(codon 67:GGC--GGT; Figure 2). The remaining seven
(22%) mobility shifts represented a common polymorphism
(GCG-+ACG; Figure 2), substituting a threonine for an
alanine at codon 148. The metastatic tumour specimens,
however, revealed no mobility shifts by SSCP.
With respect to TP53 gene alterations, 13 out of 32 (41%)
Table II Genetic alterations of the CDKN2 and TP53 genes in primary and metastatic ovarian adenocarcinomas
TP53 alteration CDKN2alteration
Tumour Nucleotide Amino acid
Sample Histology cells (%) Exon Exon Codon change change
Primary
591 Serous .25 6 2 67 GGC-.GGT Gly-+Gly
615 Serous .25 7
602 Serous .25
638 Mucinous <25 2 148 GCG-+ACG Ala-Thr
580 Mucinous .25
623 Endometrioid .25 2 148 GCG-+ACG Ala-+Thr
624 Mixed <25
604 Unknown <25 2 148 GCG-+ACG Ala-Thr
582 Serous 25 - 50 7 2 148 GCG-+ACG Ala-+Thr
603 Serous 25 - 50
657 Mucinous 25 - 50 5
601 Serous 50 - 75 8
616 Serous 50 - 75 6
626 Serous 50 - 75 8
585 Serous 50 - 75
618 Serous 50 - 75
459 Poorly differentiated 50 - 75 6
545 Mixed 50 - 75
649 Mixed 50 - 75
553 Serous .75 7
562 Serous >75
621 Serous >75
565 Mucinous >75 2 148 GCG-+ACG Ala-+Thr
620 Endometrioid >75 5
622 Endometrioid >75 6
564 Endometrioid >75 6 2 148 GCG-+ACG Ala-+Thr
605 Endometrioid >75 7 2 148 GCG-+ACG Ala-+Thr
595 Endometrioid >75
612 Endometrioid >75
625 Clear cell >75 1 23 GGT-+GGA Gly-+Gly
586 Clear cell >75
596 Serous Not determined
Metastatic
583 Serous 50 - 75 5
617 Serous 50 - 75 8
540 Serous 50 - 75
547 Serous >75 7
574 Serous >75 5CDKN2 gene alterations in ovarian cancer
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Figure 2 Sequence analysis of the CDKN2 gene in human ovarian cancer. PCR products with altered migration patterns were
analysed. (a and b) Silent mutations in codon 23 (exon 1) and 67 (exon 2). (c) A common polymorphism in codon 148 (exon 2). The
asterisks indicate the base changes. Sequences are read from bottom to top in the 5'-+3' direction.
primary tumour specimens and four out of five (80%)
metastatic tumour specimens showed altered migration
patterns on SSCP. Of the seven tumours having a
polymorphism in the CDKN2 gene three tumour specimens
showed an alteration in the TP53 gene. DNA sequencing
analysis showed that two mutations occurred in exon 7
(Arg248Trp and Arg248Leu), whereas the third mutation was
found in exon 6 (Ilel95Thr; Table II). Of the two tumours
having a silent CDKN2 gene mutation, one also showed a
mutation in exon 6 (Arg2l3stop) of the TP53 gene.
Discussion
To determine whether alterations of the CDKN2 gene may be
critical in the formation of ovarian cancer, we have analysed
primary and metastatic ovarian adenocarcinomas and
ovarian cancer cell lines for the presence of CDKN2 gene
alterations. One of the five cell lines tested, SK-OV-3, was
found to be homozygously deleted for the CDKN2 gene,
whereas another cell line, HOC-7, showed a partial deletion
of 16 bp in exon 2, resulting in a frameshift and a premature
stop codon. Okamoto et al. (1994) and Schultz et al. (1995)
also found a homozygous deletion in the cell line SK-OV-3.
Homozygous deletions have been reported in nearly 30%
(two out of seven) of ovarian cancer cell lines (Kamb et al.,
1994). Our solid ovarian tumour specimens, however, were
not indicative of homozygous deletions. Among the 32
primary ovarian adenocarcinomas studied, only two silent
mutations were found in one out of 14 serous and one out of
two clear cell tumour specimens. The common polymorphism
Alal48Thr, previously described as Alal4OThr by Cairns et
al. (1994), was observed in seven ovarian adenocarcinomas
(one out of 14 serous, two out of four mucinous, three out of
seven endometroid and one out of one unknown. We
observed no CDKN2 alterations in five metastatic tumour
samples. Campbell et al. (1995) and Schultz et al. (1995)
observed no mutations in 67 primary and five out of 40
ovarian tumours showing LOH on 9p respectively. In
addition, the latter author reported homozygous deletions
of the CDKN2 gene in 14% (16 out of 115) of ovarian
neoplasms using comparative multiplex PCR. However, 50%
of the tumours used in their study were common epithelial
tumours, whereas the other 50% were of different
histopathological subtype, mainly benign tumours.
The low prevalence of CDKN2 gene alterations observed
by us may also be explained by technical difficulties
associated with primary tumour studies. Data on analyses
ofmutations or other genetic abnormalities in tumours where
the material studied contains less then 50% tumour cells
should be interpreted with caution. For example, the presence
of homozygous deletions in tumours may be masked by a
considerable non-neoplastic cell content. Although in the
present study the majority of the tumours contained over
50% of tumour cells, we were not able to observe major
differences in signal intensities when comparing genomic
input DNA and PCR product ratios (after 30 cycles). In
addition, with respect to mutations concern may also exist.
However, Table II shows that CDKN2 and TP53 gene
mutations are equally prevalent in tumour samples with
either a smaller or a higher percentage of tumour cells. A
possible underestimation of mutations and/or deletions in
tumour tissues could be excluded by dissecting tumour cells
from surrounding normal tissue. Another explanation for the
low prevalence of CDKN2 gene mutations may be the
sensitivity of the SSCP technique. To reduce the false-
negative rate below 10%, we digested the PCR products used
in this study in order to generate fragments of less than 200
base pairs (Hayashi and Yandell, 1993). Moreover, a normal
TP53 mutation spectrum was observed since, of all tumours
studied, 46% showed a TP53 alteration as determined by
SSCP. A recent review by Shelling et al. (1995) reported that
44% (46 out of 105) ovarian tumours showed TP53
mutations, measured by SSCP.
A low frequency of CDKN2 gene alteration in tumours
and a higher frequency in cell lines has also been described in
tumours of the breast (Xu et al., 1994; Berns et al., 1995),
head and neck (Zhang et al., 1994; Lydiatt et al., 1995), lung,
bladder, kidney, brain and colon (Cairns et al., 1994; Spruck
et al., 1994). In contrast, homozygous deletions and/or
mutations occur more often in mesotheliomas (Cheng et al.,
1994), melanomas (Hussussian et al., 1994), non-small-cell
lung carcinomas (Hayashi et al., 1994), glioblastomas
(Schmidt et al., 1994) and several other tumours (Mori et
al., 1994; Caldas et al., 1994).
This study does not rule out a putative role ofmethylation
of the CDKN2 gene in ovarian cancer. De novo methylation
of the 5'CpG island of CDKN2 is a frequent abnormality in
non-small-cell lung cancer, gliomas, head and neck squamous
cell carcinoma, breast and colon cancer (Herman et al., 1995;
Merlo et al., 1995). This methylation could lead to lack of
expression of CDKN2 protein causing loss of cell cycle
control. This will be a subject for further study.
In conclusion, alterations in the CDKN2 gene are
infrequent in both primary and metastatic ovarian
adenocarcinomas, suggesting that CDKN2 gene mutations
play no significant role in the initiation or progression of
ovarian cancer. A study on an association with prognosis is
not attainable owing to the low prevalence of CDKN2
mutations. Since LOH at 9p2l has been reported in up toCDKN2 gene alterations in ovarian cancer
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50% of primary epithelial ovarian tumours (Chenevix-
Trench et al., 1994; Weitzel et al., 1994), one or more
other tumour-suppressor genes may be present in the region
of 9p21.
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